MHRA regulatory flexibilities resulting from coronavirus (COVID-19)

These temporary flexible approaches apply to clinical trials, inspections & medicines regulation e.g. there is no need to inform MHRA of a temporary halt of a clinical trial if related to COVID-19 & MHRA are no longer routinely undertaking onsite inspections.


Medicines and Healthcare products Regulatory Agency